A Prospective Cohort Study of Pralsetinib or Anlotinib in the Treatment of Locally Advanced and/or Metastatic Medullary Thyroid Carcinoma With RET Gene Mutations
Clinical trial NCT07048964 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07048964
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Status
- NOT_YET_RECRUITING
- Study type
- OBSERVATIONAL
- Start date
- 2025-08-01
- Primary completion
- 2026-02-28
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.